Description
Hovione can customize Fluticasone propionate for inhalation with an unrivalled range of particle size reduction technologies for the production of tailor made API, featuring a near-perfect particle size distribution reproducibility with a low span and amorphous content, providing highly stable API.
Hovione Fluticasone Propionate is available since 2001 and is approved in branded, generic and 505b2 applications.